Targeting CREBBP/EP300 in cancer

SRP068961

Homo sapiens

8 Downloadable Samples

Illumina HiSeq 2000

Submitter Supplied Information

Description

Antiprolifereative effects of CREBBP/EP300 inhibitors were tested in human leukemia and lymphoma cell lines and the molecular mechanisms responsible for such effects were explored. Overall design: K562 cells were treated with CBP-30 (CREBBP/EP300 bromodomain inhibitor), C646 (CREBBP/EP300 HAT activity inhibitor) and JQ1 (BRD4 inhibitor) and changes in gene expression were evaluated by RNA-seq.

PubMed ID

29884215

Publication Title

CREBBP/EP300 bromodomains are critical to sustain the GATA1/MYC regulatory axis in proliferation.

Total Samples

Submitter’s Institution

No associated institution

Authors

Garcia-Carpizo V, Ruiz-Llorente S, Sarmentero J, Graña-Castro O, Pisano DG, Barrero MJ

Source Repository

Sequence Read Archive (SRA)

No rows found